Disease · MONDO_0007803
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rasagiline Mesylate vs Placebo: serious adverse events | 29 of 84 | 23 of 90 | 174 | NCT00977665 | Trial comparisons |
| Rifampicin vs Placebo: serious adverse events | 3 of 50 | 12 of 50 | 100 | NCT01287221 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: Effect of Treatment (Epigallocatechin Gallate vs Placebo) on Safety and Tolerability: Discontinuation Rates Because of Hepatotoxicity | 2 of 47 | 0 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: Clinical Safety and Tolerability of EGCG Measured by Death Rates | 4 of 47 | 2 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: deaths from any cause | 4 of 47 | 2 of 45 | 92 | NCT02008721 | Trial comparisons |
| EGCG as Putative Neuroprotective Agent vs Placebo: serious adverse events | 18 of 47 | 8 of 45 | 92 | NCT02008721 | Trial comparisons |
| Lu AF82422 vs Placebo: deaths from any cause | 2 of 40 | 2 of 21 | 61 | NCT05104476 | Trial comparisons |
| Lu AF82422 vs Placebo: serious adverse events | 12 of 40 | 7 of 21 | 61 | NCT05104476 | Trial comparisons |
| Exenatide vs Standard of Care: Loss of Independent Ambulation | 2 of 25 | 2 of 25 | 50 | NCT04431713 | Trial comparisons |
| Exenatide vs Standard of Care: deaths from any cause | 2 of 25 | 2 of 25 | 50 | NCT04431713 | Trial comparisons |
| Exenatide vs Standard of Care: serious adverse events | 10 of 25 | 10 of 25 | 50 | NCT04431713 | Trial comparisons |
| Safinamide vs Placebo: deaths from any cause | 1 of 32 | 0 of 17 | 49 | NCT03753763 | Trial comparisons |
| Safinamide vs Placebo: serious adverse events | 2 of 32 | 0 of 17 | 49 | NCT03753763 | Trial comparisons |
| Sirolimus vs Placebo: deaths from any cause | 5 of 35 | 1 of 12 | 47 | NCT03589976 | Trial comparisons |
| Sirolimus vs Placebo: serious adverse events | 9 of 35 | 2 of 12 | 47 | NCT03589976 | Trial comparisons |
| Insulin vs Placebo: deaths from any cause | 0 of 9 | 0 of 6 | 15 | NCT02064166 | Trial comparisons |
| Insulin vs Placebo: serious adverse events | 0 of 9 | 0 of 6 | 15 | NCT02064166 | Trial comparisons |
| Lithium CARBONATE 150 or 300 mg vs Placebo: serious adverse events | 4 of 4 | 1 of 5 | 9 | NCT00997672 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007803/comparisons